This website uses cookies

This websites contains videos from YouTube. This company uses cookies (third party cookies). If you do not want them to use these cookies, you can indicate so here. However, this does mean that you will not be able to watch videos on this website. We also make use of our own cookies in order to improve our website. We don't share our data with other parties. Which cookies are involved?

This website uses cookies to enable video and to improve the user experience. If you do not want to accept these cookies, indicate so here. Which cookies are involved?

Ga direct naar de inhoud, het hoofdmenu, het servicemenu of het zoekveld.

News

04Feb 2020

Back to News overview

Impact NKI research highlighted by ASCO

Research led by Lisette Rozeman was selected by the American Society of Clinical Oncology for inclusion in the Clinical Cancer Advances 2020, which highlights the most impactful research advances of the past year.

Lisette Rozeman's research on neo-adjuvant immunotherapy in melanoma patients is featured in this annual review as a remarkable milestone in clinical cancer research and care. Last year, this OpACIN-neo study showed that many melanoma patients with lymph node metastases could benefit from this treatment, which consists of immunotherapy (see video) before instead of after surgery.

The Netherlands Cancer Institute is highly active within the research field of neo-adjuvant immunotherapy. NKI researchers investigate this innovative treatment strategy in patients with different types of cancer: skin, intestine, breast, stomach, bladder, lung, renal cell, and head and neck cancer.

 See and read more

  • Last month Lisette Rozeman won the 2019 Antoni van Leeuwenhoek Award for her excellent research into immunotherapy for melanoma patients (see video)
  • Read the news article about the OpACIN-neo study and the trend of neo-adjuvant immunotherapy here.
  • Read the research paper here
  • Check out this video to see how checkpoint inhibitors (immunotherapy) work
Share this page